Piper Sandler initiated coverage on PROCEPT BioRobotics with a new price target
$PRCT
Medical/Dental Instruments
Health Care
Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $105.00 | Overweight | Morgan Stanley |
| 11/14/2024 | $95.00 | Hold | Jefferies |
| 8/11/2023 | $42.00 | Overweight | Piper Sandler |
| 5/31/2023 | Outperform | William Blair | |
| 10/31/2022 | Neutral | BTIG Research | |
| 10/25/2022 | $58.00 | Buy | Truist |
| 9/2/2022 | $49.00 | Overweight | Wells Fargo |
| 7/15/2022 | $47.00 | Overweight | KeyBanc Capital Markets |
NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence That Procept's Vision of Addressing "All Prostates" Is Highly Exaggerated Raises Serious Concerns About Procept's Market Size Estimates, Procedure Competitiveness, and Aquablation Adoption Hurdles Questions Procedure Safety, the Quality Track Record of Procept Equipment, and the Value-Add of and Market Reception to the Company's New HYDROS System Highlights Disturbing Data Points Suggesting Growing Business Challenges, Relevance of Key Metrics, and Financial Model Concerns Estimates That Procept Shares Face 30%-60% Long-Term Potential Downside Risk Given Its Niche So
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 da
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) ("PROCEPT BioRobotics" or the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price
Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00
Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00
Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
424B5 - PROCEPT BioRobotics Corp (0001588978) (Filer)
424B5 - PROCEPT BioRobotics Corp (0001588978) (Filer)
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the prior period in 2023U.S. handpiece and consumables revenue of $29.6 million for the third quarter of 2024, an increase of 74% compared to the prior period in 2023Sold 45 robotic systems in the U.S. in the third quarter of 2024
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/yhamkcsz Dial-in registration for sell-side re
SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)